NCT04646889View on ClinicalTrials.gov

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

June 27, 2022

Study Completion Date

June 27, 2022

Conditions
Renal Impairment
Interventions
DRUG

AR882 Single Dose

A single dose of AR882

DRUG

AR882 Multiple Dose

AR882 taken once daily for 14 days

Trial Locations (4)

32809

Arthrosi Investigative Site, Orlando

75230

Arthrosi Investigative Site, Dallas

Unknown

Arthrosi Investigative Site, Auckland

Arthrosi Investigative Site, Christchurch

Sponsors
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Arthrosi Therapeutics

INDUSTRY

NCT04646889 - Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment | Biotech Hunter | Biotech Hunter